Role of sympathetic nervous system and neuropeptides in obesity hypertension

Brazilian Journal of Medical and Biological Research

Volumn 33, Issue 6, 2000, Pages 605-618

  Hall, J E ^a   Brands, M W ^a   Hildebrandt, D A ^a   Kuo, J ^a   Fitzgerald, S ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin; Kidney; Leptin; Obesity; Sodium excretion

Indexed keywords

FATTY ACID; LEPTIN; NEUROPEPTIDE; SODIUM;

ADRENERGIC SYSTEM; ANIMAL; BLOOD PRESSURE; BODY MASS; CORONARY ARTERY BLOOD FLOW; DISEASE MODEL; DOG; HUMAN; HYPERTENSION; KIDNEY; METABOLISM; NATRIURESIS; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; URINE;

ANIMALS; BLOOD PRESSURE; BODY MASS INDEX; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; DOGS; FATTY ACIDS; HUMANS; HYPERTENSION; KIDNEY; LEPTIN; NATRIURESIS; NEUROPEPTIDES; OBESITY; SODIUM; SYMPATHETIC NERVOUS SYSTEM;

EID: 0034201446     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2000000600001     Document Type: Article

References (60)

1. Stamler J (1993). Epidemic obesity in the United States. Archives of Internal Medicine, 153: 1040-1044.
2. Najjar M & Rowland M for the National Center for Health Statistics (1987). Anthropometric Reference Data and Prevalence of Overweight: United States, 1976-80. Government Printing Office. Department of Health and Human Services Publication No. (PHS) 87-1688, Washington, DC.
3. Kumanyika S (1987). Obesity in black women. Epidemiologic Reviews, 9: 31-50.
4. Wickelgren I (1998). Obesity: How big a problem? Science, 280: 1364-1367.
5. Alexander J, Dustan HP, Sims EAH & Tarazi R (1979). Report of the Hypertension Task Force. US Government Printing Office. US Department of Health, Education, and Welfare Publication No. 70-1631 (NIH), Washington, DC, 61-77.
6. Garrison RJ, Kannel WB, Stokes J & Castelli WP (1987). Incidence and precursors of hypertension in young adults: The Framingham Offspring Study. Preventive Medicine, 16: 234-251.
7. Reisen E, Abel R, Modan M, Silverberg DS, Eliahou HE & Modan B (1978). Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. New England Journal of Medicine, 198: 1-6.
8. Jones DW, Kim JS, Andrew ME, Kim SJ & Hong YP (1994). Body mass index and blood pressures in Korean men and women: The Korean National Blood Pressure Survey. Journal of Hypertension, 12 1433-1437.
9. Kissebah AH & Krakower GR (1994). Regional adiposity and morbidity. Physiological Reviews, 74: 761-811.
10. Berchtold P, Jorgens V, Finke C & Berger M (1981). Epidemiology of obesity and hypertension. International Journal of Obesity, 5 (Suppl 1 ): 1-7.
11. Hall JE, Zappe DH, Alonso-Galicia M, Granger JP, Brands MW & Kassab SE (1996). Mechanisms of obesity-induced hypertension. News in Physiological Sciences, 11: 255-261.
12. Alonso-Galicia M, Brands MW, Zappe DH & Hall JE (1996). Hypertension in obese Zucker rats: Role of angiotension II. Hypertension, 28: 1047-1054.
13. Tuck ML, Sowers J, Dornfield L, Kledzik G & Maxwell M (1981). The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. New England Journal of Medicine, 304: 930-933.
14. Landsberg L & Krieger DR (1989). Obesity, metabolism, and the sympathetic nervous system. American Journal of Hypertension, 2: 1255-1325.
15. Hall JE (1994). Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension, 23: 381-394.
16. Hall JE, Brands MW, Dixon WN & Smith Jr MJ (1993). Obesity-induced hypertension: renal function and systemic hemodynamics. Hypertension, 22: 292-299.
17. Messerli FH, Christie B, DeCarvalho JG, Aristimuno GG, Suarez DH, Dreslinski GR & Frohlich ED (1981). Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion and plasma renin activity. Archives of Internal Medicine, 141: 81-85.
18. Van Vliet BN, Hall JE, Mizelle HL, Montani J-P & Smith Jr MJ (1995). Reduced parasympathetic control of heart rate in obese dogs. American Journal of Physiology, 269: H629-H637.
19. Reisin E, Messerli FH, Ventura HO & Frohlich ED (1984). Renal hemodynamics in obese and lean essential hypertensive patients. In: Messerli FH (Editor), Kidney in Essential Hypertension. Martinus Nihoff, Boston, 125-129.
20. Carrol JF, Huang M, Hester RL, Cockrell K & Mizelle HL (1995). Hemodynamic alterations in obese rabbits. Hypertension, 26: 465-470.
21. Carroll JF, Braden DS, Cockrell K & Mizelle HL (1997). Obese rabbits develop concentric and eccentric hypertrophy and diastolic filling abnormalities. American Journal of Hypertension, 10: 230-233.
22. Gottdiener JS, Reda DJ, Materson BJ, Massie BM, Notargiacomo A, Hamburger RJ, Williams DW & Henderson WG (1994). Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. Journal of the American College of Cardiology, 24: 1492-1498.
23. Carroll JF, Braden DS, Henegar JR & Mizelle HL (1998). Dietary sodium chloride (NaCl) worsens obesity-related cardiac hypertrophy. FASEB Journal, 12 A708 (Abstract).
24. Guyton AC (1990). The surprising kidney-fluid mechanism for pressure control: Its infinite gain! Hypertension, 16: 725-730.
25. Hall JE (1997). Mechanisms of abnormal renal sodium handling in obesity hypertension. American Journal of Hypertension, 10: s49-s55.
26. Grassi G, Servalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F & Mancia G (1995). Sympathetic activity in obese normotensive subjects. Hypertension, 25: 560-563.
27. Hall JE, Van Vliet BN, Garrity CA, Torrey C & Brands MW (1993). Obesity hypertension: Role of adrenergic mechanisms. Hypertension, 21: 528 (Abstract).
28. Rocchini AP, Mao HZ, Babu K, Marker P & Rocchini AJ (1999). Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension, 33: 548-553.
29. Wofford MR, Adair C, Anderson DC, Hall JE, Miller MM & Jones DW (1998). Alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Hypertension, 32: 595 (Abstract).
30. Kassab S, Kato T, Wilkins C, Chen R, Hall JE & Granger JP (1995). Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension, 25: 893-897.
31. Zappe DH, Capel WT, Keen HL, Shek EW, Brands MW & Hall JE (1996). Role of renal afferent nerves in obesity-induced hypertension. American Journal of Hypertension, 9: 20A (Abstract).
32. Hall JE (1993). Hyperinsulinemia: A link between obesity and hypertension? Kidney International, 43: 1402-1417.
33. Hall JE, Brands MW, Zappe DH, Dixon WN, Mizelle HL, Reinhart GA & Hildebrandt DA (1995). Hemodynamic and renal responses to chronic hyperinsulinemia in obese, insulin resistant dogs. Hypertension, 25: 994-1002.
34. Hildebrandt DA, Smith Jr MJ & Hall JE (1999). Cardiovascular regulation during acute and chronic vertebral artery insulin infusion in concious dogs. Journal of Hypertension, 17: 252-260.
35. Stepniakowski KT, Goodfriend TL & Egan BM (1995). Fatty acids enhance vascular a-adrenergic sensitivity. Hypertension, 25: 774-778.
36. Grekin RJ, Dumont CJ, Vollmer AP, Watts SW & Webb RC (1997). Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion. American Journal of Physiology, 273: R324-R330.
37. Hildebrandt DA, Kirk D & Hall JE (1999). Renal and cardiovascular responses to chronic increases in cerebrovascular free fatty acids. Federation Proceedings, 13: A780 (Abstract).
38. Hall JE, Henegar JR, Shek EW & Brands MW (1997). Role of renin-angiotensin system in obesity hypertension. Circulation, 96: 1-33 (Abstract).
39. Robles RG, Villa E, Santirso R, Martinez J, Ruilope LM, Cuesta C & Sancho JM (1993). Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. American Journal of Hypertension, 6: 1009-1019.
40. Reisen E, Weir M, Falkner B, Hutchinson HG, Anzalone DA & Tuck ML (1997). Lisinopril versus hydrochlorothiazide in obese hypertensive patients. Hypertension, 30: 140-145.
41. Hildebrandt DA, Mizelle HL, Brands MW & Hall JE (1993). Systemic hemodynamic actions of long-term intravertebral angiotensin II infusion. FASEB Journal, 7: A405 (Abstract).
42. Hall JE, Shek EW & Brands MW (1999). Is leptin a link between obesity and hypertension? Current Opinion in Endocrinology and Diabetes, 6: 225-229.
43. Haynes WG, Sivitz WI, Morgan DA, Walsh SA & Mark AL (1997). Sympathetic and cardiorenal actions of leptin. Hypertension. 30 (Part II): 619-623.
44. Haynes WG, Morgan DA, Walsh SA, Sivitz WI & Mark AL (1998). Cardiovascular consequences of obesity: role of leptin. Clinical and Experimental Pharmacology and Physiology, 25: 65-69.
45. Casto RM, VanNess JM & Overton JM (1998). Effects of central leptin administration on blood pressure in normotensive rats. Neuroscience Letters, 246: 29-32.
46. Lembo G, Vecchione C, Fratta L, Marino G, Santic DD & Trimarco B (1998). Leptin induces nitric-oxide mediated vasorelaxation in aortic-rings of WKY rats. Hypertension, 32: 599 (Abstract).
47. Flier JS & Maratos-Flier E (1998). Obesity and the hypothalamus: novel peptides for new pathways. Cell, 92: 437-440.
48. McAuley MA, Chen X & Westfall TC (1993). Central cardiovascular actions of neuropeptide Y. In: Colmers WF & Wahlestedt C (Editors), The Biology of Neuropeptide Y and Related Peptides. Humana Press, New Jersey, 389-418.
49. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P & Lee F 11997). Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell, 88: 131-141.
50. Fan W, Boston BA, Kesterson RA, Hruby VJ & Cone RD (1997). Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature, 385: 165-168.
51. Thornton JE, Chueng CC, Clifton DK & Steiner RA (1994). Regulation of hypothalamic proopiomelanocortin mRNA by leptm in ob/ob mice. Nature, 372: 425-432.
52. Haynes WG, Morgan DA, Djalali A, Sivitz WI & Mark AL (1999). Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension, 33 (Part II): 542-547.
53. Shek EW, Brands MW & Hall JE (1998). Chronic leptin infusion increases arterial pressure. Hypertension, 31 (Part II): 409-414.
54. Ogawa Y, Masuzaki H, Aizawa M, Yura S, Satoh N, Iwai H, Hosoda K & Nakao K (1998). Blood pressure elevation in transgenic mice over-expressing leptin, the obese gene product. Journal of Hypertension, 16: S7 (Abstract).
55. Shek EW, Kim PK & Hall JE (1999). Adrenergic blockade prevents leptin-induced hypertension. Federation Proceedings, 13: A456 (Abstract).
56. VanHeek M, Comptom DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD & Davis HR (1997). Diet-induced obese mice develop peripheral, but not central, resistance to leptin. Journal of Clinical Investigation, 99: 385-390.
57. Lu H, Duanmu Z, Houck C, Jen KL, Buison A & Dunbar JC (1998). Obesity due to high fat diet decreases the sympathetic nervous and cardiovascular responses to intracerebroventricular leptin in rats. Brain Research Bulletin, 47: 331-335.
58. Hirose H, Saito I, Tsujioka M, Mori M, Kawabe H & Saruta T (1998). The obese gene product, leptin: possible role in obesity-related hypertension in adolescents. Journal of Hypertension, 16: 2007-2012.
59. Suter PM, Locher R, Häsler E & Vetter W (1998). Is there a role for the ob gene product leptin in essential hypertension? American Journal of Hypertension, 11: 1305-1311.
60. Onions KL, Hunt SC, Rutkowski MP, Klanke CA, Su YR, Reif M & Menon AG (1998). Genetic markers at the leptin (ob) locus are not significantly linked to hypertension in African Americans. Hypertension, 31: 1230-1234.